After hours: March 21 at 7:19:28 PM EDT Loading Chart for MDGL ...

Madrigal said that all patients enrolled in MAESTRO-NASH - which include up to 2,000 in total - are continuing on therapy after the initial 52-week treatment period.

Madrigal Pharma has become the first drugmaker to claim FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH), an elusive target that has seen many other ...